Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
10).Interestingly, somatic activating mutations in MTOR with low mutational burden (e.g., mutated allele frequency of ~1% in the affected tissue) have been shown to be sufficient to lead to intractable focal epilepsy (4).The molecular mechanism of how somatic activating mutations in MTOR cause intractable epilepsy, however, has remained elusive.mTOR kinase is a major regulator of translation, which is a fundamental molecular mechanism regulating gene expression (11).Translational dysregulation is thought to underlie the molecular pathogenesis of various human diseases, particularly cancers and neurodevelopmental disorders, as they are associated with the aberrant activation of mTOR (11,12).Accordingly, we hypothesized that translational dysregulation induced by human MTOR mutations may underlie the molecular pathogenesis of intractable epilepsy and other pathologies found in FMCD.However, owing to a lack of disease models of single activating mutations in MTOR, we found understanding of the molecular basis of translational dysregulation directly induced by human MTOR mutations to be lacking: previous studies of mTOR-driven translational control have relied on pharmacological inhibition of mTOR (13, 14).To date, translational profiles in disease models with single MTOR mutations are not available, and questions of how human MTOR mutations lead to disease, which genes are controlled, and how they are regulated remain largely unanswered.In this study using FMCD mouse models, genome-edited cells, and patient brain Brain somatic mutations confer genomic diversity in the human brain and cause neurodevelopmental disorders.Recently, brain somatic activating mutations in MTOR have been identified as a major etiology of intractable epilepsy in patients with cortical malformations.However, the molecular genetic mechanism of how brain somatic mutations in MTOR cause intractable epilepsy has remained elusive.In this study, translational profiling of intractable epilepsy mouse models with brain somatic mutations and genome-edited cells revealed a novel translational dysregulation mechanism and mTOR activation-sensitive targets mediated by human MTOR mutations that lead to intractable epilepsy with cortical malformation.These mTOR targets were found to be regulated by novel mTOR-responsive 5′-UTR motifs, distinct from known mTOR inhibition-sensitive targets regulated by 5′ terminal oligopyrimidine motifs.Novel mTOR target genes were validated in patient brain tissues, and the mTOR downstream effector eIF4E was identified as a new therapeutic target in intractable epilepsy via pharmacological or genetic inhibition.We show that metformin, an FDA-approved eIF4E inhibitor, suppresses intractable epilepsy.Altogether, the present study describes translational dysregulation resulting from brain somatic mutations in MTOR, as well as the pathogenesis and potential therapeutic targets of intractable epilepsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724 · cited 7×
“To assess enrichment of gene ontology categories, mTOR activation– sensitive genes in FMCD and C1483Y cells and mTOR inhibition–sensitive genes in Torin1 cells were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) (https:// david.ncifcrf.gov), version 6.7 (42); ClueGO (http:/…”
MethodInfluentialFunction and regulation of CREB family transcription factors in the nervous system
Lonze, B. E., & Ginty, D. D. (2002) · Neuron · doi:10.1016/s0896-6273(02)00828-0 · Cited by 2,127
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313 · cited 9×
“PRTE motif is a broad motif that encompasses 5′ TOP or 5′ TOP–like motifs (14).”
BackgroundResultInfluentialMorita, M., Gravel, S.-P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.001 · Cited by 842 · cited 1×
“Consistent with our findings, other studies have provided evidence suggesting that activation of the mTOR pathway leads to increased translation of a subset of mitochondrial and energy production–related mRNAs (43, 44) and that 5′ TOP genes are insensitive to the activation of mTOR (45, 46).”
ResultRNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Regulation of Dendritic Morphogenesis by Ras–PI3K–Akt–mTOR and Ras–MAPK Signaling Pathways
Kumar, V., Zhang, M.-X., Swank, M. W., Kunz, J., & Wu, G.-Y. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2284-05.2005 · Cited by 588
The mTOR signalling cascade: paving new roads to cure neurological disease
Crino, P. B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.81 · Cited by 368 · cited 1×
“Translational dysregulation is thought to underlie the molecular pathogenesis of various human diseases, particularly cancers and neurodevelopmental disorders, as they are associated with the aberrant activation of mTOR (11, 12).”
BackgroundRubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200
Cited by
The Neurodevelopmental Pathogenesis of Tuberous Sclerosis Complex (TSC)
Feliciano, D. M. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00039 · Cited by 69
“Perhaps most striking is the fact that somatic mutations that cause mTORC1 pathway activation have been identified as a cause of a plethora of neurological diseases (Lee et al., 2012; Poduri et al., 2012; Parker et al., 2013; Lal et al., 2014; Baek et al., 2015; Baulac et al., 2015; Crino, 2015; D’Gama et al., 2015, 2…”
BackgroundNext-generation sequencing methodologies to detect low-frequency mutations: “Catch me if you can”
Menon, V., & Brash, D. E. (2023) · Mutation Research - Reviews in Mutation Research · doi:10.1016/j.mrrev.2023.108471 · Cited by 48
Lee, W. S., Baldassari, S., Stephenson, S. E. M., Lockhart, P. J., Baulac, S., & Leventer, R. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031344 · Cited by 45
Metadata
- Authors
- Kim, J. K., Cho, J., Kim, S. H., Kang, H.-C., Kim, D.-S., Kim, V. N., & Lee, J. H.
- Venue
- Journal of Clinical Investigation
- Published
- 2019-09-04
- Volume
- 129
- Issue
- 10
- Pages
- 4207-4223
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2972471297
- Cited by
- 66
- References
- 12
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy. https://app.cochat.ai/papers/10.1172/jci127032
- The paper
- Kim, J. K., Cho, J., Kim, S. H., Kang, H.-C., Kim, D.-S., Kim, V. N., & Lee, J. H. (2019). Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy. Journal of Clinical Investigation. https://doi.org/10.1172/jci127032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.